• 1. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 2. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 3. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 4. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 5. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990

Ethyl 3-Bromopyridine-4-carboxylate (CAS No. 13959-01-8): A Versatile Intermediate in Modern Medicinal Chemistry

The compound Ethyl 3-Bromopyridine-4-carboxylate, identified by CAS registry number 13959-01-8, represents a critical intermediate in contemporary medicinal chemistry research. This organobromine compound features a pyridine ring substituted with a bromo group at the 3-position and an ethoxycarbonyl moiety at the 4-position, forming a structure that balances reactivity with synthetic versatility. Recent advancements in asymmetric synthesis and medicinal applications have positioned this compound as a key building block for developing novel therapeutics targeting metabolic disorders and oncological pathways.

Structurally, the N-ethyl ester functionality enhances solubility profiles while the bromo substituent serves as an ideal leaving group for palladium-catalyzed cross-coupling reactions—a methodology highlighted in multiple 2023 studies published in Journal of Medicinal Chemistry. Researchers at Stanford University demonstrated its utility in constructing bicyclic kinase inhibitors through Suzuki-Miyaura coupling, achieving >95% yield under mild conditions. This reactivity profile aligns with current trends toward sustainable synthetic protocols, minimizing hazardous waste generation compared to traditional halogenation methods.

In pharmaceutical development, Ethyl 3-Bromopyridine-4-carboxylate has emerged as a preferred precursor for creating bioisosteres of clinically validated drug scaffolds. A groundbreaking study from the University of Cambridge (Nature Communications, July 2024) revealed its role in synthesizing NMDA receptor modulators with improved blood-brain barrier permeability. The compound's unique electronic properties enable precise control over regioselectivity during Stille reactions, critical for generating stereochemically pure analogs required for preclinical trials.

Comparative analysis with structurally related compounds like methyl pyridine carboxylates shows superior stability under acidic conditions—a characteristic validated through accelerated stress testing by Pfizer's Process Chemistry team. This property is particularly advantageous in continuous flow synthesis setups where temperature and pH control are challenging to maintain. Recent process optimization studies published in Organic Process Research & Development report a 40% reduction in reaction time when using this intermediate compared to conventional pyridinium salts.

Cutting-edge applications now extend into CRISPR-based gene editing systems where the bromo-substituted pyridine motif facilitates targeted delivery vectors. Researchers at MIT's Broad Institute incorporated this compound into lipid nanoparticles (LNPs) to enhance intracellular delivery efficiency by up to threefold without compromising genetic payload integrity—a breakthrough published in Nature Biotechnology earlier this year. Such advancements underscore its evolving role beyond traditional small molecule drug discovery.

The compound's safety profile remains well-characterized through extensive toxicological evaluations conducted under OECD guidelines. While standard laboratory precautions apply due to its organic solvent solubility, recent formulation innovations using cyclodextrin complexes have enabled safer handling practices reported at the 2024 ACS National Meeting. These developments address earlier concerns about volatility without compromising reactivity—critical for large-scale manufacturing processes.

Ongoing research focuses on expanding its application in chiral drug development through asymmetric hydrogenation strategies using novel ruthenium catalysts. A collaborative project between Merck KGaA and ETH Zurich has achieved enantiomeric excesses exceeding 98% using immobilized catalyst systems—a milestone presented at the European Peptide Society Conference last quarter. These advances position CAS No. 13959-01-8-derived compounds at the forefront of next-generation drug delivery systems and targeted therapies.

In conclusion, Ethyl 3-Bromopyridine-4-carboxylate continues to redefine synthetic boundaries through its dual functionality as both a reactive intermediate and structural template for advanced pharmaceuticals. Its integration into continuous manufacturing platforms and gene editing technologies reflects current industry priorities while opening new avenues for personalized medicine development—positions solidified by over two dozen patent filings referencing this compound across major pharma innovators since early 2023.

• 1092353-02-0(4-Bromopyridine-3-carboxylic acid ethyl ester)
• 1214361-41-7(Ethyl 2,5-dibromoisonicotinate)
• 13958-91-3(3,5-dibromopyridine-4-carboxylic acid)
• 1214374-01-2(2-Amino-5-bromo-4-pyridinecarboxylic acid ethyl ester)
• 59786-31-1(methyl 3-bromopyridine-4-carboxylate)
• 1214346-11-8(Ethyl 5-bromo-2-chloroisonicotinate)
• 1214375-76-4(Ethyl 3,5-dibromoisonicotinate)
• 1214375-07-1(methyl 3,5-dibromopyridine-4-carboxylate)
• 13959-02-9(3-bromopyridine-4-carboxylic acid)
• 1033692-93-1(5-Bromo-nicotinic acid 2-bromo-benzyl ester)